David Raben insider trades: Bicara Therapeutics (BCAX) stock sales
Trades on the price chart
Daily close, with an arrow on each day they bought or sold
Companies
Where David reports to the SEC
Open-market buys and sales
3 trades reported on SEC Form 4, newest first
| Date | Stock | Type | Shares | Price | Value | Holding | Reported |
|---|---|---|---|---|---|---|---|
| Mar 4, 2026 | BCAX | ↓ Sell | 16,500 | $18.52 | $306K | Direct | Mar 5, 2026 (1d) |
| Nov 25, 2025 | BCAX | ↓ Sell | 11,000 | $18.65 | $205K | Direct | Nov 25, 2025 (0d) |
| Oct 9, 2025 | BCAX | ↓ Sell | 22,000 | $18.45 | $406K | Direct | Oct 10, 2025 (1d) |
Each row is one filing's trades in one stock, summed. Shares and prices are as filed, before any later stock split.
Other BCAX insiders
Open-market trades in the last 12 months
About David Raben's insider trades
David Raben is Chief Medical Officer at Bicara Therapeutics (BCAX). Since Oct 9, 2025, David has reported no open-market purchases and 3 sales worth $917K on SEC Form 4. In the last 12 months: 2 sales ($511K).
Their filings also include option exercises (3 filings), grants and awards (2 filings). These aren't open-market trades and aren't counted above.
How to read insider trades
Officers, directors and owners of more than 10% of a company must report trades in its stock on SEC Form 4, usually within two business days. Purchases with their own money are the stronger signal: insiders sell for many reasons (taxes, diversification, a house), but buy for one. See every BCAX insider trade, the latest insider trades across the market, or cluster buys, when several insiders buy the same stock within days.